Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living ...

Progressing on a decade-long path to a global travel management program, pharmaceutical company Pfizer this year completed a 24-country agency consolidation in Europe, the Middle East and Africa.

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few ...

The big drugmaker should be even bigger over the next five years despite facing a patent cliff. It's a different story today. Sales for Pfizer's COVID-19 vaccine have declined significantly. The ...

I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to ...

Pfizer is a Buy for medium- to long-term investors, trading at a low P/E and undervalued versus peers, with strong non-COVID growth. Strategic pivots include aggressive R&D, cost-cutting, and the ...

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive ...

Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. HUNTSVILLE, Ala. – Operation Warp Speed has ...

Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) anti-PD-1 therapy Keytruda, succeeded in a Phase 3 pivotal trial for ...